MiNK Therapeutics, Inc. Common Stock
Veridion Score
Composite trend over time
Why is INKT moving today?
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for INKT.
INKT insider activity
MiNK Therapeutics, Inc. Common Stock
5 insiders bought in the last 90 days
Net buying: $720K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-05 | 2026-06-04 | Ryan Barbara | Insider | sell | $12.80 | 1,000 | 21,969 | $13K | SEC Form 4 |
| 2026-06-05 | 2026-06-04 | Ryan Barbara | Insider | sell | $12.68 | 500 | 22,969 | $6K | SEC Form 4 |
| 2026-06-02 | 2026-06-01 | Holcomb John Bradley | Insider | buy | $12.38 | 1,091 | 3,458 | $14K | SEC Form 4 |
| 2026-06-02 | 2026-06-01 | Behner Peter | Insider | buy | $12.38 | 1,313 | 22,919 | $16K | SEC Form 4 |
| 2026-06-02 | 2026-06-01 | Ryan Barbara | Insider | buy | $12.38 | 1,434 | 23,469 | $18K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 28 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moINKT contract awards, year to date.
Public federal awards linked to this ticker.
INKT lobbying filings, year to date.
Registered lobbying filings matched to MiNK Therapeutics, Inc. Common Stock.